source
- Cullinan and Taiho report six-month survival gain for EGFR exon 20 NSCLC in phase 3 trialCullinan Therapeutics and Taiho Oncology presented interim data from their phase 3 Rezilient3 study, which evaluated the tyrosine kinase inhibitor zipalertinib combined with platinum‑based chemothe…
- GSK’s risvutatug rezetecan shows 18.5-month median overall survival in phase 3 SCLC trialGSK, together with Chinese partner Hansoh Pharma, reported results of its antibody‑drug conjugate risvutatug rezetecan (ris‑rez) in a phase 3 trial for relapsed small‑cell lung cancer. The study e…